Survodutide for the Treatment of Obesity
Year: 2024
Type: article
Study design: Study Protocol
Abstract: Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, double-blind, parallel-group, event-driven, CV safety study of survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly compared with placebo in adults with a body mass index ≥27 kg/m2 and established CV disease or chronic kidney disease, and/or at least 2 weight-related complications or risk factors for CV disease. The primary endpoint of SYNCHRONIZE-CVOT is time to first occurrence of the composite adjudicated endpoint of 5-point major adverse CV events. This global CV outcomes trial is currently enrolling, with a target recruitment of 4,935 participants. SYNCHRONIZE-CVOT is the first trial that will determine the CV safety and efficacy of survodutide in people with obesity and increased CV risk. (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity [SYNCHRONIZE–CVOT]; NCT06077864)
Source: JACC Heart Failure
Institutions: Saint Luke's Hospital, University of Missouri–Kansas City, Brigham and Women's Hospital, Harvard University, University of Toronto, University College Dublin, St. Vincent's University Hospital, Heidelberg University, University Medical Centre Mannheim, Boehringer Ingelheim (Germany), Dartmouth College, Dartmouth Health
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,750
Funder: Boehringer Ingelheim
OpenAlex ID: W4403673786
